Autres langues

24/08 BriaCell Therapeutics Corp. Advances Personalized Melanoma Immunotherapy Vaccine Candidate Bria-MEL+
24/08 BriaCell Therapeutics : Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+(TM)
24/08 BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
05/08 BriaCell Gets FDA Approval to Start Phase 1/2a of Prostate Cancer Immunotherapy Study
05/08 Briacell Therapeutics Corp Receives Fda Clearance to Initiate Bria-Pros+ Clinical Study in Prostate Cancer
05/08 BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
16/07 BriaCell Opens First Canadian Site For Phase 3 Metastatic Breast Cancer Study
16/07 BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT
16/07 BriaCell Therapeutics Corp. Opens First Canadian Site For Pivotal Phase 3 Trial In Metastatic Breast Cancer
16/07 BriaCell Therapeutics : Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer
16/07 BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
15/07 BriaCell Therapeutics : Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT(TM)
15/07 BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
07/07 BriaCell Engages Consulting and Branding Firms to Support Potential Commercialization of Bria-IMT
07/07 BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
25/06 BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT
25/06 BriaCell Therapeutics Inks MOU With Dutch Microneedle Company
25/06 BriaCell Therapeutics : Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)
25/06 BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
09/06 BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2026
02/06 BriaCell Therapeutics Rises After Hours as It Closes a $4.7-Million Share Offering
02/06 BriaCell Therapeutics Closes $4.7 Million Share Offering
02/06 BriaCell Therapeutics Announces Closing of Offering
01/06 BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting
01/06 BriaCell Presents Positive Clinical Data at ASCO 2026
Aucun résultat pour cette recherche
🔇